Air Liquide has just completed the acquisition of DinnoSanté, a company that specialises in medical-technical services for diabetes.
Air Liquide, reportedly number one in the European homecare market, has just completed the 100% acquisition of DinnoSanté, a company that specialises in medical-technical services for diabetes.
DinnoSanté is a French company with 90 employees which specializes in the equipment and home monitoring of patients with diabetes. It supplies nearly 2,300 chronic diabetes patients with equipment designed to facilitate their lives, including insulin pumps and glucose meters, and supporting them with personalised training and regular follow-up.
This acquisition reinforces Air Liquide’s offer in taking charge of pathologies that are treatable at home: sleep apnea (frequent in patients with diabetes), and chronic respiratory disease for example.
Pascal Vinet, Vice-President, Healthcare World Business Line and Healthcare Operations for the Air Liquide Group, commented, “This new Healthcare acquisition illustrates our development strategy which seeks to strengthen our global range of services related to homecare treatments. Health is a solid and promising growth driver for the Air Liquide Group.”
Diabetes is a major chronic illness whose development is in large part linked to changes in lifestyle as well as an ageing population. In France, more than 2.5 million people are being treated for diabetes, a figure that is constantly rising. Advances in treatment technologies and the growing use of insulin pumps help to improve the quality of life of the patients by giving them greater mobility as well as greater flexibility of use.
Meanwhile, Air Liquide has also just obtained an extended approval from the French Healthcare Authority (AFSSAPS).
Air Liquide obtained the approval from AFSSAPS for its analgesic medication KALINOX™. This premix of 50% nitrous oxide and 50% oxygen medicinal gas offers a new response to the issues of short painful medical treatments (such as punctures, minor surgeries and dental care) in ambulant care services.
Already used in France for nearly 10 years, but exclusively in hospitals, KALINOX™ has contributed to improve pain management efficiency. Extending its use beyond the hospital to local healthcare practitioners in France - after training - will help them to handle painful, often anxiety-producing treatments, many of which, up to now, had been carried out exclusively in hospitals.
Already used by local healthcare practitioners in Belgium, Switzerland and Spain, KALINOX™ is a medicinal gas with analgesic and sedative properties, appropriate for use with all patients: children, adults and the elderly.
Vinet explained in a statement, “Making KALINOX™ available to healthcare professionals in the community is part of our growth strategy and also contributes to reducing healthcare costs. Air Liquide is pursuing its strategy of innovating in ways that protect patients and improve their quality of life. Health is a growth driver for the group.”